Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GPCR
GPCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GPCR News
Truist Initiates Coverage on VKTX with Buy Rating and $83 Price Target
3d ago
stocktwits
Deep Track Capital Increases Stake in Structure Therapeutics
May 24 2026
Fool
Deep Track Capital Increases Stake in Structure Therapeutics
May 24 2026
NASDAQ.COM
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape
May 20 2026
Fool
HighVista Strategies Sells Shares of Structure Therapeutics
May 17 2026
Fool
ACT Capital Management Fully Exits Structure Therapeutics Stake
May 10 2026
Fool
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
Apr 28 2026
stocktwits
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
Apr 22 2026
stocktwits
Structure Therapeutics Appoints New COO
Apr 14 2026
seekingalpha
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Apr 07 2026
Barron's
SPDR S&P China ETF Analysts See 34.69% Upside
Apr 03 2026
NASDAQ.COM
Wegovy Pill Shows Superior Weight Loss Over Foundayo
Apr 02 2026
CNBC
Viking and Structure Intensify Competition in Obesity Drug Development
Mar 30 2026
stocktwits
B Group Initiates Position in Structure Therapeutics
Mar 22 2026
Fool
B Group Acquires Shares in Structure Therapeutics
Mar 22 2026
NASDAQ.COM
Novo Nordisk's High-Dose Wegovy Approved by FDA
Mar 19 2026
CNBC
Show More News
